FGP
AMPH icon

Freestone Grove Partners’s Amphastar Pharmaceuticals AMPH Stock Holding History

Freestone Grove Partners’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$585K Buy
29,857
+2,264
+8% +$55.4K ﹤0.01% 571
2025
Q4 		$739K Buy
+27,593
New +$711K 0.01% 503

Other funds holding AMPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

Freestone Grove Partners's AMPH Position: Q1 2026 in Review

Freestone Grove Partners increased its Amphastar Pharmaceuticals (AMPH) stake by 8.2% in Q1 2026, buying an estimated $55.4K and bringing the position to 29,857 shares worth $585K. The position accounts for ﹤0.01% of the portfolio, ranked #571.

Freestone Grove Partners first reported a position in AMPH in Q4 2025 and has held it in 2 quarters since. The position peaked at $739K in Q4 2025. 215 funds tracked by Wall St. Rank hold AMPH as of Q1 2026.

  • Freestone Grove Partners held 29,857 shares of Amphastar Pharmaceuticals worth $585K as of Q1 2026.
  • Freestone Grove Partners bought 2,264 Amphastar Pharmaceuticals shares in Q1 2026, an estimated $55.4K.
  • Amphastar Pharmaceuticals made up ﹤0.01% of Freestone Grove Partners's portfolio in Q1 2026, its #571 holding.
  • Freestone Grove Partners first reported a position in Amphastar Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Freestone Grove Partners's Amphastar Pharmaceuticals position peaked at $739K in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.